Clinical trials: Degenerative Conditions, Neurologic
Muscular Atrophy, Spinal
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2…
- Trial name
- HINALEA 1 (NCT05861986)
- Testing
- Risdiplam
- Where
- 16 sites in United States, Germany and 2 more
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This is a Phase II, multicenter, open-label, single arm, PD study in participants with early (prodromal to mild) AD to evaluate the effect of a once weekly (Q1W) dosing regimen of gantenerumab on deposited amyloid as measured by…
- Trial name
- NCT04592341
- Testing
- Gantenerumab
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 192 people
- Sponsor
- Hoffmann-La Roche
Degenerative Disc Disease
Adipose Cells for Degenerative Disc Disease
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed degenerative disc disease.
- Trial name
- NCT02097862
- Testing
- Adipose Stem Cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bioheart, Inc.
Parkinson's Disease
SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)
The objective of the Post Marketing Surveillance Study is to investigate the use of the non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy in patients with Morbus Parkinson.
- Trial name
- NCT00727727
- Testing
- Piribedil
- Where
- 2 sites in Germany
- Volunteers
- 750 people
- Sponsor
- Desitin Arzneimittel GmbH
Parkinson Disease
Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease
This expanded access protocol is part of IND 027396 to evaluate efficacy and safety of multiple intravenous administrations of autologous HB-adMSCs for the treatment of Parkinson's disease for up to 11 patients who passed…
- Trial name
- NCT06056427
- Testing
- HB- adMSCs (Hope Biosciences adipose derived mesenchymal stem cells)
- Sponsor
- Hope Biosciences Research Foundation
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- DAYBREAK-ALZ (NCT02783573)
- Testing
- Lanabecestat
- Where
- 262 sites in United States, Canada and 16 more
- Volunteers
- 1,722 people
- Sponsor
- AstraZeneca
Amyotrophic Lateral Sclerosis
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month…
- Trial name
- MITOTARGET (NCT00868166)
- Testing
- Olesoxime, Riluzole
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 512 people
- Sponsor
- Hoffmann-La Roche
Wilson Disease
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their…
- Trial name
- NCT07226622
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Prime Medicine, Inc.
Cognition Disorder, Alzheimer Disease
Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856
This is a Phase 0, open-label, non-controlled, single-centre study designed to evaluate the pharmacokinetics (PK) and safety and tolerability of a single, bolus intravenous (iv) injection of a microdose of ACD856 in healthy…
- Trial name
- NCT05783830
- Testing
- ACD856
- Where
- Sweden
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AlzeCure Pharma
Parkinson Disease
A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
When a patient with Parkinson's disease (PD) is initially treated with L-dopa or dopamine agonists, the symptoms of PD improve or disappear.
- Trial name
- NCT01155466
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 778 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
- Trial name
- NCT01766336
- Testing
- Group 1 ELND005, Group 2 ELND005
- Where
- 46 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- OPKO Health, Inc.
Alzheimer's Type Dementia
A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
- Trial name
- NCT01276353
- Testing
- E2020
- Where
- 11 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Charcot-Marie-Tooth Disease
Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls
The primary aim of this study is to discover whether patients with CMT type 1 and 2 have neuromuscular junction transmission deficits.
- Trial name
- ESTABLISH (NCT04980807)
- Where
- 2 sites in United States, Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NMD Pharma A/S
Alzheimer's Disease
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate…
- Trial name
- NOURISH-AD (NCT01741194)
- Testing
- AC-1204
- Where
- 82 sites in United States
- Volunteers
- 418 people
- Sponsor
- Cerecin
Parkinson Disease
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25…
- Trial name
- NCT06722729
- Testing
- KDT-3594
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Myasthenia Gravis
The Impact of Myasthenia Gravis in the Real World
An international, non-interventional, prospective, community recruited, longitudinal, lifestyle study which aims to collect Real-World Evidence (RWE) from people living with myasthenia gravis (MG) in order to map the disease's…
- Trial name
- NCT04176211
- Where
- United Kingdom
- Volunteers
- 2,847 people
- Sponsor
- Vitaccess Ltd
Alzheimer Disease, Dementia
PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
This is a prospective, multicentric, randomized, double blind, placebo controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 therapy along with standard supportive care in subjects with mild to…
- Trial name
- NCT04052737
- Testing
- Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment
- Where
- 5 sites in India
- Volunteers
- 80 people
- Sponsor
- Pharmazz, Inc.
Cystic Fibrosis, Motor Neuron Disease
MN4000 for Treatment of CF and MND Patients in the Home Setting
The study was a non-randomized open label pilot study. It was an observational design conducted at one (1) site in the US. All enrolled subjects received treatment with the MN4000.
- Conditions
- Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
- Trial name
- NCT03797677
- Testing
- MN 4000
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Parkinson Disease
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics
The purpose of the study was to To investigate whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose…
- Trial name
- NCT03094156
- Testing
- BIA 6-512, Madopar® 250, Comtan®
- Where
- Portugal
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer's Disease
Extension Study of Participants From SPG302-ALZ-101
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALZ-101 with mild to moderate Alzheimer's Disease (AD)
- Trial name
- NCT06833281
- Testing
- SPG302
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Spinogenix
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.